Plus Therapeutics GAAP EPS of -$0.29 beats by $0.01, revenue of $5.21M beats by $0.14M
Source: SeekingAlpha
2026-03-12 16:53:47 ET
More on Plus Therapeutics
- Plus Therapeutics, Inc. (PSTV) Discusses Business Update, REYOBIQ Clinical Program Progress, and Recent Financial Offering - Slideshow
- Plus Therapeutics, Inc. (PSTV) Discusses Business Update, REYOBIQ Clinical Program Progress, and Recent Financial Offering Transcript
- Plus Therapeutics, Inc. (PSTV) Presents at 2025 San Antonio Breast Cancer Symposium (SABCS) - Slideshow
- Plus Therapeutics stock plunges after pricing $15M units offering
- Seeking Alpha’s Quant Rating on Plus Therapeutics
Read the full article on Seeking Alpha
For further details see:
Plus Therapeutics GAAP EPS of -$0.29 beats by $0.01, revenue of $5.21M beats by $0.14M
PLUS THERAPEUTICS Inc.
NASDAQ: PSTV
PSTV Trading
-5.51% G/L:
$0.2281 Last:
2,475,041 Volume:
$0.243 Open:
PSTV Latest News
March 26, 2026 07:30:00 am
Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors
March 19, 2026 07:30:00 am
Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%
March 12, 2026 04:15:00 pm
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ(TM) Clinical Program and CNSide® Commercial Rollout
February 25, 2026 07:30:00 am
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ(TM)
PSTV Stock Data
$37,787,078
135,702,904
0.32%
20
N/A
Biotechnology & Life Sciences
Healthcare
US
Houston
